Table 6. Excess hazards models of cancer patients by site, diagnostic interval 1 and symptom category 2 .
Cancer site / Diagnostic interval 1 | All Patients | Alert Symptoms | Non-alert Symptoms | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | ||||||||||||||||||||||
Excess Hazards Ratio | 95% Confidence Interval | Excess Hazards Ratio | 95% Confidence Interval | p-value | Excess Hazards Ratio | 95% Confidence Interval | Excess Hazards Ratio | 95% Confidence Interval | p-value | Excess Hazards Ratio | 95% Confidence Interval | Excess Hazards Ratio | 95% Confidence Interval | p-value | |||||||||||||
Breast³ | |||||||||||||||||||||||||||
< 1 week | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||||||||||||||
1–2 weeks | 1.14 | 0.93 | - | 1.39 | 1.04 | 0.86 | - | 1.25 | 0.674 | 1.12 | 0.91 | - | 1.38 | 1.02 | 0.84 | - | 1.23 | 0.850 | 3.01 | 0.36 | - | 25.54 | Convergence not achieved; too few events | ||||
3–4 weeks | 0.77 | 0.61 | - | 0.98 | 0.85 | 0.68 | - | 1.05 | 0.136 | 0.73 | 0.57 | - | 0.93 | 0.80 | 0.64 | - | 1.00 | 0.055 | 3.52 | 0.43 | - | 28.52 | |||||
> 1 month | 0.73 | 0.59 | - | 0.92 | 0.88 | 0.71 | - | 1.09 | 0.234 | 0.77 | 0.61 | - | 0.96 | 0.90 | 0.73 | - | 1.12 | 0.346 | 1.21 | 0.15 | - | 9.55 | |||||
Colorectal 4 | |||||||||||||||||||||||||||
<1 month | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||||||||||||||
1–2 months | 0.89 | 0.78 | - | 1.00 | 0.94 | 0.82 | - | 1.07 | 0.343 | 0.80 | 0.64 | - | 0.99 | 0.86 | 0.68 | - | 1.09 | 0.216 | 0.91 | 0.78 | - | 1.05 | 0.94 | 0.79 | - | 1.12 | 0.493 |
3–6 months | 0.83 | 0.74 | - | 0.93 | 0.92 | 0.82 | - | 1.04 | 0.174 | 0.71 | 0.57 | - | 0.87 | 0.80 | 0.64 | - | 1.00 | 0.053 | 0.79 | 0.69 | - | 0.90 | 0.93 | 0.80 | - | 1.08 | 0.349 |
>6 months | 0.98 | 0.87 | - | 1.11 | 0.93 | 0.81 | - | 1.07 | 0.326 | 1.07 | 0.82 | - | 1.41 | 0.99 | 0.74 | - | 1.32 | 0.961 | 0.80 | 0.69 | - | 0.92 | 0.85 | 0.72 | - | 1.00 | 0.049 |
Lung 5 | |||||||||||||||||||||||||||
<1 month | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||||||||||||||
1–2 months | 0.97 | 0.89 | - | 1.06 | 1.02 | 0.93 | - | 1.11 | 0.648 | 0.87 | 0.70 | - | 1.08 | 0.99 | 0.78 | - | 1.25 | 0.919 | 0.96 | 0.87 | - | 1.05 | 1.00 | 0.91 | - | 1.11 | 0.916 |
3–6 months | 0.84 | 0.78 | - | 0.91 | 0.90 | 0.84 | - | 0.98 | 0.014 | 0.71 | 0.56 | - | 0.90 | 0.79 | 0.62 | - | 1.02 | 0.069 | 0.81 | 0.74 | - | 0.88 | 0.87 | 0.80 | - | 0.95 | 0.001 |
>6 months | 0.89 | 0.82 | - | 0.96 | 0.87 | 0.80 | - | 0.94 | 0.001 | 0.93 | 0.69 | - | 1.27 | 0.97 | 0.70 | - | 1.36 | 0.872 | 0.83 | 0.76 | - | 0.90 | 0.81 | 0.74 | - | 0.89 | 0.000 |
Prostate 6 | |||||||||||||||||||||||||||
<1 month | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||||||||||||||||
1–2 months | 0.49 | 0.33 | - | 0.73 | 0.64 | 0.42 | - | 0.98 | 0.042 | 0.52 | 0.17 | - | 1.63 | Convergence not achieved; high survival in last group | 0.45 | 0.30 | - | 0.69 | 0.51 | 0.32 | - | 0.82 | 0.006 | ||||
3–6 months | 0.40 | 0.27 | - | 0.58 | 0.72 | 0.49 | - | 1.05 | 0.084 | 0.51 | 0.17 | - | 1.54 | 0.34 | 0.23 | - | 0.51 | 0.58 | 0.38 | - | 0.88 | 0.010 | |||||
>6 months | 0.16 | 0.07 | - | 0.38 | 0.45 | 0.27 | - | 0.75 | 0.002 | 0.38 | 0.07 | - | 2.03 | 0.12 | 0.05 | - | 0.33 | 0.37 | 0.21 | - | 0.64 | 0.000 |
¹time between first symptom presentation in primary care and diagnosis
²symptoms were categorized as alert or non-alert based on the NICE guidelines
³adjusted for age, sex, ethnicity, level of deprivation, morphology, tumour differentiation, number of consultations, treatment and comorbidity
4adjusted for age, sex, ethnicity, Duke stage, level of deprivation, morphology, tumour differentiation, tumour subsite, number of consultations, treatment and comorbidity
5adjusted for age, sex, ethnicity, tumour grade, smoking status, level of deprivation, morphology, number of consultations, treatment and comorbidity
6adjusted for age (15–54, 55–64, 64–74, 75+), ethnicity, tumour differentiation, level of deprivation, morphology, number of consultations, treatment and comorbidity